Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HK1 | P19367 | 2/20 | 0.53 |
| ▸ | HK2 | P52789 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.48 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.48 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextrose SCHEMBL19252827 | 0.87 | HK1 (0.53) | HK1HK2POLBLGALS9LGALS1 | |
| Ribose (Furanose) SCHEMBL2324435 | 0.85 | F2 (0.52) | HK1HK2RECQLBLMLGALS9 | |
| Ribose (Furanose) SCHEMBL17315074 | 0.85 | F7 (0.56) | HK1HK2ALDH1A1 | |
| Dextrose SCHEMBL28181167 | 0.84 | HK1 (0.59) | HK1HK2POLBLGALS9LGALS1 | |
| Ribose (Furanose) SCHEMBL338518 | 0.84 | F7 (0.59) | HK1HK2CYP3A4TSHRPMP22 | |
| Ribose (Furanose) SCHEMBL14321532 | 0.84 | F7 (0.59) | HK1HK2CYP3A4TSHRPMP22 | |
| Ribose (Furanose) SCHEMBL18185139 | 0.84 | F7 (0.59) | HK1HK2CYP3A4TSHRPMP22 | |
| Ribose (Furanose) SCHEMBL23111913 | 0.83 | F7 (0.58) | HK1HK2ALDH1A1LMNASMN1; SMN2 | |
| Ribose (Furanose) SCHEMBL18280884 | 0.83 | F7 (0.54) | HK1HK2ALDH1A1 | |
| Ribose (Furanose) SCHEMBL25392429 | 0.82 | F7 (0.52) | HK1HK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230096781-A1 | METHODS OF CONTROLLING BODYWEIGHT BY MODULATING PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE BETA ACTIVITY | UNIVERSITY OF CINCINNATI (US) | 2023-03-30 | — | — | US | claimed |
| EP-4114963-A1 | METHODS OF CONTROLLING BODYWEIGHT BY MODULATING PHOSPHATIDYLINOSITOL 5-PHOSPHATE 4-KINASE BETA ACTIVITY | University of Cincinnati (US) | 2023-01-11 | — | — | EP | claimed |
| US-20180318388-A1 | COMPOSITIONS AND METHODS FOR SENSITIZING LOW RESPONSIVE TUMMORS TO CANCER THERAPY | PANDURANGI RAGHOOTTAMA (US) | 2018-11-08 | — | — | US | claimed |
| EP-3368056-A1 | COMPOSITIONS AND METHODS FOR SENSITIZING LOW RESPONSIVE TUMORS TO CANCER THERAPY | Pandurangi, Raghoottama (US) | 2018-09-05 | — | — | EP | claimed |
| WO-2017131911-A1 | COMPOSITIONS AND METHODS FOR SENSITIZING LOW RESPONSIVE TUMORS TO CANCER THERAPY | PANDURANGI RAGHOOTTAMA (US) | 2017-08-03 | — | — | WO | claimed |
| EP-1765336-A2 | ANGIOGENESIS INHIBITORS | THE JOHNS-HOPKINS UNIVERSITY (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006004795-A2 | ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-01-12 | — | — | WO | claimed |
| US-20050113321-A1 | DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor | FURMAN PHILIP A (US) | 2005-05-26 | — | — | US | claimed |
| WO-2004009595-A1 | COMBINATION THERAPY WITH 1,3-DIOXOLANES AND INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORS | TRIANGLE PHARMACEUTICALS, INC. (US) | 2004-01-29 | — | — | WO | claimed |
| EP-1363704-A2 | DAPD COMBINATION THERAPY WITH INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITOR | Triangle Pharmaceuticals Inc. (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030148966-A1 | Method and composition for inducing apoptosis in cells | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE OF INDIANA UNIVERSITY | 2003-08-07 | — | — | US | claimed |
| US-20020173491-A1 | DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor | GILEAD SCIENCES, INC. | 2002-11-21 | — | — | US | claimed |
| WO-2002068058-A2 | DAPD COMBINATION THERAPY WITH IMDPH INHIBITORS SUCH AS RIBAVIRIN OR MYCOPHENOLIC ACID | TRIANGLE PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | claimed |
| CN-1292795-A | Certain dinucleotides and their use as membrana mucosa cilium clearing and cilium vibration frequency regulating agent | INSPIRE PHARMACEUTICALS INC (US) | 2001-04-25 | — | — | CN | claimed |
| US-5902792-A | Method of inducing apoptosis in cancer cells | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (US) | 1999-05-11 | — | — | US | claimed |
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | THE BROAD INSTITUTE, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-3368056-B1 | COMPOSITIONS AND METHODS FOR SENSITIZING LOW RESPONSIVE TUMORS TO CANCER THERAPY | PANDURANGI RAGHOOTTAMA (US) | 2025-08-20 | — | — | EP | disclosed |
| CN-1250369-A | Method of treating dry eye disease with purinergic receptor agonists | INSPIRE PHARMACEUTICALS INC (US) | 2000-04-12 | — | — | CN | disclosed |
| US-5902792-A | Method of inducing apoptosis in cancer cells | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (US) | 1999-05-11 | — | — | US | disclosed |
| US-5902792-A | Method of inducing apoptosis in cancer cells | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE (US) | 1999-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113321-A1 | DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2, AMPD1 | HK1 2581/4885HK2 3865/4885POLB 660/4885 |
| US-20020173491-A1 | DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2, AMPD1 | HK1 2945/4885HK2 4051/4885POLB 842/4885 |
| US-12590288-B2 | Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response | GPR3, GALR3, NR4A3 | HK1 954/4885HK2 1164/4885POLB 4545/4885 |
| US-20180318388-A1 | COMPOSITIONS AND METHODS FOR SENSITIZING LOW RESPONSIVE TUMMORS TO CANCER THERAPY | NGFR, TNFRSF1A, PSMA1 | HK1 705/4885HK2 1274/4885POLB 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.